Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2003
09/23/2003US6624140 Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
09/23/2003US6623962 Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors
09/23/2003US6623947 Nucleotide sequences coding pancreatic protein; for use in the treatment of diabetes and pancreatic defects
09/23/2003US6623942 Nucleotide sequences coding polypetide for use in treatment of hematopoietic and immunological disorders; wound healing agents
09/23/2003US6623940 Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
09/23/2003US6623938 Human I-FLICE (Inhibitor of FLICE (FADD-like ICE)) polynucleotides; vectors, host cells and recombinant methods for producing the same
09/23/2003US6623934 For isolation of proteins that may be used to induce bone and/or cartilage or other connective tissue formation, and in wound healing and tissue repair
09/23/2003US6623926 Methods for producing 5′-nucleic acid-protein conjugates
09/23/2003US6623923 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
09/23/2003US6623748 Reverse phase connective tissue repair composition
09/23/2003US6623742 By administering a Clostridial toxin to a peripheral location on the body of a patient
09/23/2003US6623741 Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
09/23/2003US6623740 Peptide having an amino acid sequence set forth in SEQ ID NO: 3, 5, 9, 11, 13, 14 or 15
09/23/2003US6623738 Polypeptide consisting of amino acid sequence 2 or 4 which is not cross reactive with mouse, chick nor drosophila neuro-pilin-1
09/23/2003US6623736 Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
09/23/2003US6623734 Super absorption coenzyme Q10
09/23/2003US6623733 Harvesting tissue cells; lysing and filtering; administering angiogenic filtrate
09/23/2003US6623732 Active polypeptide, taurine and hyaluronic acid; nonirrating
09/23/2003US6623731 Modified amino acid compounds useful in the drug delivery of bioactive agents such as recombinant human growth hormone (rhGH); dosage units; synthesis
09/23/2003US6623472 Method for inducing therapeutically-effective proteins
09/23/2003CA2314865C Methods for preventing and treating mastitis
09/23/2003CA2218555C Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
09/23/2003CA2147482C Process for manufacturing crystals of growth hormone and crystals thereby obtained
09/23/2003CA2112907C Peptide which abrogates tnf and/or lps toxicity
09/23/2003CA2085781C Bradykinin-antagonists for the treatment of acute pancreatitis
09/23/2003CA2082424C Analogs of glycoprotein hormones having altered immunological characteristics, efficacy and/or receptor specificity
09/23/2003CA2068027C Pharmaceutical compositions comprising an anticytokine
09/18/2003WO2003076950A2 Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders
09/18/2003WO2003076664A1 Antisense modulation of jagged 2 expression
09/18/2003WO2003076658A2 A susceptibility gene for late-onset idiopathic parkinson's disease
09/18/2003WO2003076647A2 Jade nucleic acids, proteins and uses thereof
09/18/2003WO2003076642A2 Novel proteins and nucleic acids encoding same
09/18/2003WO2003076634A2 Transcriptional regulation of ptp-1b
09/18/2003WO2003076631A2 Genetic products differentially expressed in tumors and use thereof
09/18/2003WO2003076625A1 Proteolysis resistant active vegf
09/18/2003WO2003076621A2 Vpr modulators and uses thereof
09/18/2003WO2003076617A1 Transporter selectively transporting sulfate conjugate and its gene
09/18/2003WO2003076594A2 Genomic screen for epigenetically silenced tumor suppressor genes
09/18/2003WO2003076593A2 Genomic screen for epigenetically silenced genes associated with cancer
09/18/2003WO2003076586A2 Nucleic acid-associated proteins
09/18/2003WO2003076585A2 Controlled modulation of amino acid side chain length of peptide antigens
09/18/2003WO2003076584A2 Novel proteins and nucleic acids encoding same
09/18/2003WO2003076583A2 Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria
09/18/2003WO2003076579A2 Cancer-linked gene as target for chemotherapy
09/18/2003WO2003076578A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/18/2003WO2003076577A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/18/2003WO2003076572A2 Novel nucleic acid molecules and polypeptides encoding baboon tafi
09/18/2003WO2003076571A2 Cancer-linked gene as target for chemotherapy
09/18/2003WO2003076569A2 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
09/18/2003WO2003076567A2 Heterologous g-csf fusion proteins
09/18/2003WO2003076565A2 Methods of using 46828, a human acyl-coa synthetase
09/18/2003WO2003076490A1 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
09/18/2003WO2003076469A2 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature
09/18/2003WO2003076467A1 Compositions and methods for inducing and regulating bone formation
09/18/2003WO2003076464A2 Mutagenesis of aspergillus fungi and identification of genes essential for growth
09/18/2003WO2003076461A2 Dimeric tf antagonist comprising two factor vii polypeptides
09/18/2003WO2003076460A1 A process for the production of ramoplanin-like amide derivatives
09/18/2003WO2003076458A2 Selective dipeptide inhibitors of kallikrein
09/18/2003WO2003076457A1 INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME
09/18/2003WO2003076391A2 Urokinase inhibitors, production and use thereof
09/18/2003WO2003075977A2 Agglomerated particles for aerosol drug delivery
09/18/2003WO2003075960A1 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
09/18/2003WO2003075958A1 Remedies for sex hormone-dependent disease
09/18/2003WO2003075957A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
09/18/2003WO2003075953A2 Immunomodulatory polymeric antigens for treating inflammatory pathogies
09/18/2003WO2003075952A1 Methods of enhancing immune induction involving mda-7
09/18/2003WO2003075951A2 Novel application of vaccination against tnf-alpha
09/18/2003WO2003075950A1 Minimising body weight gain in insulin treatment
09/18/2003WO2003075949A1 Method and composition for treating skin wounds with epidermal growth factor
09/18/2003WO2003075948A1 NOVEL FUNCTION OF Wnt AND APPLICATION THEREOF TO TREATMENT OF DISEASES
09/18/2003WO2003075947A1 Use of egfr transactivation inhibitors in human cancer
09/18/2003WO2003075946A2 Treatment of type i diabetes mellitus using growth hormone antagonist
09/18/2003WO2003075945A2 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis
09/18/2003WO2003075944A2 Interferon beta-like molecules for treatment of stroke
09/18/2003WO2003075903A2 Use proline and its functional equivalentsfor quenching ros and/ or radicals
09/18/2003WO2003075892A1 Pharmaceutical microparticles
09/18/2003WO2003075887A1 Sustained release drug formulations containing a carrier peptide
09/18/2003WO2003075885A1 Composition having gelling properties for the prolonged delivery of bioactive substances
09/18/2003WO2003075856A2 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
09/18/2003WO2003075848A2 Inhibitors for use in hemostasis
09/18/2003WO2003075841A2 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
09/18/2003WO2003075839A2 Methods of inducing terminal differentiation
09/18/2003WO2003075834A2 Activated protein c formulations
09/18/2003WO2003075746A2 Methods for aneurysm repair
09/18/2003WO2003075741A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
09/18/2003WO2003068815A3 Mhc class ii peptide epitope of 5t4 antigen
09/18/2003WO2003059296A3 Compositions comprising collagen and metalloprotease inhibitors
09/18/2003WO2003054015A3 Use of coagulant-active antitrhombin iii for the therapy of angiogenesis-dependent diseases
09/18/2003WO2003051848A3 Imidazolidineacetic acid derivatives
09/18/2003WO2003050247A3 Antisense modulation of mhc class ii transactivator expression
09/18/2003WO2003049700A3 Growth hormone releasing hormone suplementation for treating chronically ill subjects
09/18/2003WO2003048735A3 Processes for the measurement of the potency of glatiramer acetate
09/18/2003WO2003039454A8 Beta-secretase inhibitors and methods of use
09/18/2003WO2003037363A3 Non-neurotoxic plasminogen activating factors for treating stroke
09/18/2003WO2003037273B1 Method of use of erythropoietin to treat ischemic acute renal failure
09/18/2003WO2003035861A3 Thrombin-cleavable chimeric proteins
09/18/2003WO2003035105A3 A synthetic chimeric fusion protein with immuno-therapeutic uses
09/18/2003WO2003033808A3 Composition and method for treating diabetes
09/18/2003WO2003032928A3 Therapeutic composition and use
09/18/2003WO2003031584A3 Axon repair
1 ... 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 ... 3163